Story
NeOnc Technologies Shares Surge on Positive Phase 2 Glioma Trial Data

Shares of NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI) surged after the company announced positive topline results from its Phase 2a clinical trial of NEO100 in patients with a recurrent form of brain cancer. The company's stock rose 11.7% following the news.
Key Trial Results
The study, which evaluated intranasal NEO100 in patients with recurrent IDH1-mutant high-grade glioma, successfully met its primary endpoint. The trial demonstrated a six-month progression-free survival (PFS) rate of 48.9%, significantly higher than the pre-specified benchmark of 20% for standard of care, with a p-value of 0.0047.
The trial enrolled 24 patients with Grade III and Grade IV tumors that had progressed after initial treatment. According to NeOnc, key secondary and other endpoints included:
- Median overall survival reached 26.09 months.
- 86.7% of patients were alive at the six-month mark.
- The objective response rate was 8.3%, with two patients achieving a response.
Safety Profile and Next Steps
AdThe company reported that NEO100, which is self-administered by patients at home four times daily, was well-tolerated. No major toxicities were observed, and adverse events were described as predominantly low-grade. Five patients from the study remain on active treatment.
NeOnc Technologies plans to request a Type B meeting with the U.S. Food and Drug Administration (FDA) to discuss a registrational development path for NEO100. This is a critical step toward potential market approval. The company noted that there are currently no approved targeted therapies for this specific patient population—recurrent IDH1-mutant high-grade glioma.
Market Context
This indication represents a significant unmet medical need. While other IDH-targeted agents have been approved, they are for lower-grade disease in the front-line setting, not for patients with recurrent high-grade tumors like those in the NEO100 trial.
NeOnc stated it expects to present the full dataset from the Phase 2a study, including detailed safety and pharmacokinetic data, at a future medical conference. Further analyses are currently ongoing.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.